Senesco Technologies

Senesco Technologies

Biotechnology, 721 Us Hwy 202206, Bridgewater, New Jersey, 08807, United States, 1-10 Employees

senesco.com

  • LinkedIn

Who is SENESCO TECHNOLOGIES

Senesco is running a Phase 1/2 study in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma patients with a novel gene regulatory approach. The ability of eukaryotic ...

Read More

map
  • 721 Us Hwy 202206, Bridgewater, New Jersey, 08807, United States Headquarters: 721 Us Hwy 202206, Bridgewater, New Jersey, 08807, United States
  • 1998 Date Founded: 1998
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541711 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from SENESCO TECHNOLOGIES

Senesco Technologies Org Chart and Mapping

Employees

Similar Companies to Senesco Technologies

EVRAZ North America

  • 1001-5000 1001-5000
  • 250 Million to 500 Million $ 250 Million to 500 Million
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Senesco Technologies

Answer: Senesco Technologies's headquarters are located at 721 Us Hwy 202206, Bridgewater, New Jersey, 08807, United States

Answer: Senesco Technologies's official website is https://senesco.com

Answer: Senesco Technologies's revenue is $5 Million to $10 Million

Answer: Senesco Technologies's SIC: 8731

Answer: Senesco Technologies's NAICS: 541711

Answer: Senesco Technologies has 1-10 employees

Answer: Senesco Technologies is in Biotechnology

Answer: Senesco Technologies top competitors include: EVRAZ North America

Answer: Senesco Technologies contact info: Phone number: Website: https://senesco.com

Answer: Senesco is running a Phase 1/2 study in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma patients with a novel gene regulatory approach. The ability of eukaryotic translation initiation factor 5A (eIF5A) to modulate critical pathways involved in cancer and inflammatory diseases is being investigated.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access